Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Dong-A St Co. Ltd. currently manages 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. This portfolio is distributed across 4 distinct examiners and 4 distinct art units, indicating a broad spread of examination oversight. The one-to-one ratio between pending actions and examiners suggests that no single individual is handling a concentrated portion of the active workload. This distribution requires the applicant to manage 4 separate prosecution timelines simultaneously.
The busiest examiner identified in the data is ONDACHI, PAULINE WANJIKU MUCH, who is responsible for 1 pending office action. Because the 4 pending actions are split among 4 distinct examiners, the prosecution strategy involves navigating the specific preferences of multiple officials. Practitioners should prepare for varied feedback across the 4 distinct art units involved in these filings. Each unit may apply different interpretations of pharmaceutical patentability standards, necessitating a flexible approach to response drafting.
With 4 distinct examiners and 4 distinct art units for only 4 pending office actions, the company lacks the efficiency of a concentrated examination path. This diversity in oversight means that successful arguments in one case may not necessarily influence the outcomes in others. The presence of 4 pending office actions across such a wide administrative range highlights the need for careful coordination to ensure consistent claim language and disclosure across the entire Biotechnology & Pharmaceuticals portfolio.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 2 (50%) |
| §112 only | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ONDACHI, PAULINE WANJIKU MUCH | 1 | 100.0% | +0.0% |
| HELM, CARALYNNE E | 1 | 28.9% | +49.8% |
| ADLAM, CHANTAL PETA-GAYE | 1 | 53.5% | +27.8% |
| MARTIN, KEVIN STEPHEN | 1 | 77.4% | +23.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18861369 | BICYCLE COMPOUNDS AS TEAD INHIBITOR | ONDACHI, PAULINE WANJIKU MUCH | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18688439 | PERCUTANEOUS ABSORPTION PREPARATION FOR TREATING DEMENTIA COMPRISING MEMANTINE ENANTHATE | HELM, CARALYNNE E | 23d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17906742 | AMINOPYRIMIDINE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | MARTIN, KEVIN STEPHEN | 56d overdue |
| 18688439 | PERCUTANEOUS ABSORPTION PREPARATION FOR TREATING DEMENTIA COMPRISING MEMANTINE ENANTHATE | HELM, CARALYNNE E | 23d overdue |
| 17906745 | PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | ADLAM, CHANTAL PETA-GAYE | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| 1615 | 1 |
| 1622 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18861369 | BICYCLE COMPOUNDS AS TEAD INHIBITOR | ONDACHI, PAULINE WANJIKU MUCH | 1627 | §102 | Non-Final OA | — | Pending | Oct 29, 2024 |
| 18688439 | PERCUTANEOUS ABSORPTION PREPARATION FOR TREATING DEMENTIA COMPRISING MEMANTINE ENANTHATE | HELM, CARALYNNE E | 1615 | §103§112 | Final Rejection | 23d overdue | Pending | Mar 01, 2024 |
| 17906745 | PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | ADLAM, CHANTAL PETA-GAYE | 1622 | §102 | Non-Final OA | — | Pending | Sep 19, 2022 |
| 17906742 | AMINOPYRIMIDINE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | MARTIN, KEVIN STEPHEN | 1624 | §112 | Final Rejection | 56d overdue | Pending | Sep 19, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDong-A St Co. Ltd. has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Pauline Wanjiku Much Ondachi has the most, with 1 of Dong-A St Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
